VolitionRx issues shares to Lind on convertible note conversions
Two conversions in September 2026 covered $465,000 of obligations under senior secured convertible notes tied to a 2025 purchase agreement.
VolitionRx Limited disclosed in an 8-K dated September 9, 2026 that it issued additional common shares to Lind Global Asset Management XII LLC to satisfy conversion obligations under previously issued convertible notes.
The notes trace back to a securities purchase agreement dated May 15, 2025, later amended and restated on January 7, 2026, under which VolitionRx issued Lind senior secured convertible promissory notes in original principal amounts of $7,500,000 and $2,400,000.1
Under that arrangement, VolitionRx issued Lind 706,214 shares of common stock on September 2, 2026 to satisfy a $250,000 conversion obligation, and issued 707,236 more shares on September 10, 2026 to satisfy a $215,000 conversion obligation.1
The company said the share offerings were made in reliance on exemptions under Section 3(a)(9) or alternatively Section 4(a)(2) of the Securities Act, and/or Rule 506 of Regulation D, and that the issuances went to an existing securityholder without paid commissions, public offering, or general solicitation.1
Following these conversions, VolitionRx reported 27,903,326 shares of its $0.001 par value common stock issued and outstanding as of September 14, 2026.1
The filing was signed on September 15, 2026 by Cameron Reynolds, VolitionRx's Chief Executive Officer and President, as indicated in the signature block of the report.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.